阿托伐他汀钙联合依达拉奉治疗脑梗死患者的效果

Clinical Effect of Atorvastatin Calcium Combined with Edaravone in the Treatment of Patients with Cerebral Infarction

目的:探讨阿托伐他汀钙联合依达拉奉治疗脑梗死患者的效果。方法:选取2019年7月-2020年7月宜春市人民医院收治的98例脑梗死患者进行研究,按照随机数字表法分为对照组(n=49)和研究组(n=49),对照组应用依达拉奉治疗,研究组应用阿托伐他汀钙联合依达拉奉治疗。观察分析两组患者的临床疗效、不良反应、美国国立卫生研究院卒中量表(NIHSS)评分、Barthel评分、血清指标、血脂指标及血液流变学指标。结果:治疗2周后,与对照组相比,研究组总有效率更高(P<0.05);治疗2周后,研究组不良反应发生率低于对照组(P<0.05)。治疗2周后,与对照组相比,研究组NIHSS评分更低(P<0.05),Barthel评分更高(P<0.05);与对照组相比,研究组血清同型半胱氨酸(Hcy)、神经元特异性烯醇化酶(NSE)、尿酸(UA)及超敏C反应蛋白(hs-CRP)水平均更低(P<0.05);与对照组相比,研究组总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均更低,高密度脂蛋白胆固醇(HDL-C)水平更高(P<0.05);与对照组相比,研究组血小板凝聚率、全血浆黏度及血栓形成系数均更低(P<0.05)。结论:与单纯应用依达拉奉治疗相比,阿托伐他汀钙联合依达拉奉治疗脑梗死效果更为显著,能够降低炎症因子及Hcy、NSE等水平,改善患者的血液流变学指标,有利于进一步改善神经功能缺损情况,显著提高其日常生活能力,值得大力推广。

Objective:To investigate the effect of Atorvastatin Calcium combined with Edaravone in the treatment of patients with cerebral infarction.Method:A total of 98 patients with cerebral infarction admitted to Yichun People’s Hospital from July 2019 to July 2020 were selected for this study.They were divided into control group (n=49) and study group (n=49) by random number table method.The control group was treated with Edaravone,and the study group was treated with Atorvastatin Calcium combined with Edaravone.Clinical efficacy,adverse reactions,NIHSS score,Barthel score,serum indexes,blood lipid indexes and hemorheological indexes of the two groups were observed and analyzed.Result:After 2 weeks of treatment,compared with the control group,the total effective rate of the study group was higher (P<0.05);after 2 weeks of treatment,the incidences of adverse reactions in the study group was lower than that in the control group (P<0.05).After 2 weeks of treatment,compared with the control group,the NIHSS score of the study group was lower (P<0.05),and Barthel score was higher (P<0.05);compared with the control group,the levels of homocysteine (Hcy),neuron specific enolase (NSE),uric acid (UA) and high-sensitivity C-reactive protein (hs-CRP) in the study group were lower (P<0.05);compared with the control group,the levels of total cholesterol (TC),triglyceride (TG) and low density lipoprotein (LDL-C) in the study group were lower,and the levels of high density lipoprotein (HDL-C) was higher (P<0.05);compared with the control group,the platelet aggregation rate,whole plasma viscosity and thrombosis coefficient of the study group were lower (P<0.05).Conclusion:Compared with the treatment of Edaravone alone,the combined treatment of Atorvastatin Calcium with Edaravone has a more significant effect on cerebral infarction,which reduces the levels of inflammatory factors,Hcy,NSE and other factors,improves the hemorheological indexes of patients,and is conducive to further improving the neurological function deficit and significantly improving their ability of daily life,it is worthy of promotion.